New obesity drug HRS9531 takes on semaglutide in major trial

NCT ID NCT07285902

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 study tests whether a new weekly injection called HRS9531 works better than semaglutide for weight loss in 572 adults with obesity. Participants receive either drug for 52 weeks, and researchers measure changes in body weight, waist size, and BMI. The trial is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HRS9531 injection

What this could lead to

If successful, HRS9531 could offer a new weekly injection option for weight loss that is more effective than current treatments like semaglutide.

What could go wrong

This is a phase 3 trial, but results are not yet available. The new drug may not prove superior or could have unexpected side effects compared to semaglutide.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chiness PLA General Hospital

    Beijing, Beijing Municipality, 100853, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, 210029, China